ECSP034672A - Derivados de quinuclidina novedosos y composiciones medicinales que los contienen - Google Patents

Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Info

Publication number
ECSP034672A
ECSP034672A EC2003004672A ECSP034672A ECSP034672A EC SP034672 A ECSP034672 A EC SP034672A EC 2003004672 A EC2003004672 A EC 2003004672A EC SP034672 A ECSP034672 A EC SP034672A EC SP034672 A ECSP034672 A EC SP034672A
Authority
EC
Ecuador
Prior art keywords
group
hydrogen
carbon atoms
lower alkyl
substituted
Prior art date
Application number
EC2003004672A
Other languages
English (en)
Inventor
Albero Maria Antonia Buil
Forner Maria Dolors Fernandez
Maria Quinones
Original Assignee
Almirall Prodesfarma A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma A G filed Critical Almirall Prodesfarma A G
Publication of ECSP034672A publication Critical patent/ECSP034672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I): en donde B es un anilo fenilo, un grupo heteroaromático de 5 a 10 miembros que contiene un grupo benzo[1, 3] dioxolilo, o bifenilo, R1, R2 Y R3 cada uno independientemente representa un átomo de hidrógeno o halógeno, o un grupo hidroxi, un grupo fenilo, -OR7. -SR7, -NR7R8, -grupo alquilo inferior sustituido o sin sustituir, en donde R7 y R8 cada uno independientemente representa un átomo de hidrógeno, un grupo alquilo inferior recto o ramificado o conjuntamente forman un anilo alicíclico o R1 y R2 conjuntamente forman un anillo aromático o alicíclico o un grupo heterocíclico. n es un enteri de 0 a 4; A representa un grupo seleccionado entre - CH2-,CH=CR9-, CR9=CH-, CR9R10-, C0-, -=-, -S-, -S(0)-, -S(0)2 y-NR9-, en donde R9 y R10 cada uno independientemente representa un átomo de hidrógeno, un grupo alquilo recto o ramificado de alquilo inferior o conjuntamente forman un anillo alicíclico, m es un entero de 0 a 8, siempre que cuando m=0, A no es -CH2-, Pes un entero de 1 a 2 y la sustitución del anillo bicíclico de azonia puede ser en la posición 2, 3 0´ 4 incluyendo todas las configuraciones posibles de los carbonos asimétricos; R4 representa un grupo de estructura. En donde R11 Representa un átomo de hidrogeno o halógeno, un grupo hidroxi, un grupo alcoxi, un grupo nitro, un grupo ciano, -C02R12, o NR12R13, en donde R12 y R13 son idénticos o diferentes y son seleccionados entre hidrógeno y grupos de alquilo inferior recto o ramificado, sustituido o no sustituido; R5 representa un grupo alquilo de 1 a 7 átomos de carbono, un grupo alquenilo que contiene 2 a 7 átomos de carbono, un grupo alquinilo que contiene 2 a 7 átomos de carbono , un grupo cicloalquilo de 3 a 7 átomos de carbono, o un grupo de la fórmula en donde q= 1 0 2 y R11 es tal como se define anteriormente; R6 representa un átomo de hidrógeno, un grupo hidroxi, un grupo metilo, o un grupo CH2OH. El carbono asimétrico en la posición alfa con respecto al grupo ester, que es sustituido por R4, R5 y R6 puede tener una configuración R 0 S; X -representa un anion farmacéuticamente aceptable de un ácido mono o polivalente.
EC2003004672A 2000-12-28 2003-06-25 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen ECSP034672A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003130 2000-12-28

Publications (1)

Publication Number Publication Date
ECSP034672A true ECSP034672A (es) 2003-08-29

Family

ID=8496180

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004672A ECSP034672A (es) 2000-12-28 2003-06-25 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Country Status (33)

Country Link
US (4) US7122558B2 (es)
EP (1) EP1353919B1 (es)
JP (1) JP4295985B2 (es)
KR (1) KR100869721B1 (es)
CN (1) CN1250545C (es)
AR (1) AR032072A1 (es)
AT (1) ATE334128T1 (es)
AU (1) AU2002238471B2 (es)
BG (1) BG66162B1 (es)
BR (1) BR0116624A (es)
CA (1) CA2433128C (es)
CY (1) CY1105719T1 (es)
CZ (1) CZ301209B6 (es)
DE (1) DE60121813T2 (es)
DK (1) DK1353919T3 (es)
EC (1) ECSP034672A (es)
EE (1) EE05404B1 (es)
ES (1) ES2266291T3 (es)
HU (1) HUP0303524A3 (es)
IL (2) IL156558A0 (es)
MX (1) MXPA03005862A (es)
MY (1) MY136067A (es)
NO (1) NO328772B1 (es)
NZ (1) NZ526674A (es)
PE (1) PE20020721A1 (es)
PL (1) PL363807A1 (es)
PT (1) PT1353919E (es)
RU (1) RU2282629C2 (es)
SI (1) SI1353919T1 (es)
SK (1) SK287414B6 (es)
UA (1) UA75626C2 (es)
WO (1) WO2002053564A2 (es)
ZA (1) ZA200305008B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
KR100869721B1 (ko) * 2000-12-28 2008-11-21 알미랄 에이쥐 신규한 퀴누클리딘 유도체 및 그를 함유한 의약 조성물
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
AU2002321711A1 (en) * 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
AU2005247105B2 (en) * 2004-05-31 2010-11-11 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2279777A2 (en) 2007-01-10 2011-02-02 Irm Llc Compounds and compositions as channel activating protease inhibitors
MX2009008509A (es) * 2007-02-09 2009-08-20 Astellas Pharma Inc Compuesto de anillo puenteado-aza.
MX2009008323A (es) * 2007-02-15 2009-08-13 Argenta Discovery Ltd Derivados heterociclicos como receptores muscarinicos m3.
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
BRPI0816219B8 (pt) * 2007-09-07 2021-05-25 Theravance Biopharma R&D Ip Llc compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
EP2222637A1 (en) * 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8329729B2 (en) 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
BR112016000629B1 (pt) * 2013-07-13 2023-10-31 Beijing Showby Pharmaceutical Co., Ltd. Compostos de quinina e isômeros ópticos, método de preparação e utilização médica dos mesmos
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465834A (en) * 1965-09-20 1984-08-14 Fmc Corporation Anticholinergic drugs
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4082756A (en) * 1971-04-16 1978-04-04 Colgate-Palmolive Company Quaternary quinuclidinium carbamates and thiocarbamates
EP0052645B1 (en) * 1980-06-03 1987-05-13 Research Corporation Gamma-emitting receptor-binding quinuclidinyl benzilates methods of preparation thereof and imaging and assay methods utilizing same
US4431627A (en) * 1980-06-03 1984-02-14 Research Corporation Gamma-emitting receptor-binding 3-quinuclidinyl glycolates; methods of preparation thereof and imaging and assay methods utilizing same
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
IL72788A (en) * 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
WO1992004346A1 (en) * 1990-09-06 1992-03-19 Pfizer Limited Antimuscarinic bronchodilators
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0863141B1 (en) * 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
SI1300407T2 (sl) 2000-06-27 2011-09-30 S A L V A T Lab Sa Karbamati, izvedeni iz arilalkilaminov
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
KR100869721B1 (ko) * 2000-12-28 2008-11-21 알미랄 에이쥐 신규한 퀴누클리딘 유도체 및 그를 함유한 의약 조성물

Also Published As

Publication number Publication date
US7122558B2 (en) 2006-10-17
US20070105897A1 (en) 2007-05-10
MXPA03005862A (es) 2005-09-08
HK1055739A1 (en) 2004-01-21
WO2002053564A2 (en) 2002-07-11
JP4295985B2 (ja) 2009-07-15
CY1105719T1 (el) 2010-12-22
NO328772B1 (no) 2010-05-10
NZ526674A (en) 2005-03-24
SK287414B6 (sk) 2010-09-07
CZ20031812A3 (en) 2004-05-12
EP1353919A2 (en) 2003-10-22
CZ301209B6 (cs) 2009-12-09
HUP0303524A2 (hu) 2004-01-28
US7879874B2 (en) 2011-02-01
RU2282629C2 (ru) 2006-08-27
BR0116624A (pt) 2003-12-23
HUP0303524A3 (en) 2008-03-28
MY136067A (en) 2008-08-29
CA2433128A1 (en) 2002-07-11
CN1250545C (zh) 2006-04-12
JP2004517123A (ja) 2004-06-10
DK1353919T3 (da) 2006-11-20
RU2003123120A (ru) 2005-01-10
PL363807A1 (en) 2004-11-29
WO2002053564A3 (en) 2002-10-31
IL156558A (en) 2009-06-15
PT1353919E (pt) 2006-11-30
ZA200305008B (en) 2005-01-26
IL156558A0 (en) 2004-01-04
NO20033002L (no) 2003-06-30
CN1487938A (zh) 2004-04-07
KR20030067726A (ko) 2003-08-14
AU2002238471B2 (en) 2007-06-28
AR032072A1 (es) 2003-10-22
CA2433128C (en) 2010-05-25
EP1353919B1 (en) 2006-07-26
US20040072863A1 (en) 2004-04-15
DE60121813D1 (de) 2006-09-07
EE200300312A (et) 2003-10-15
NO20033002D0 (no) 2003-06-30
PE20020721A1 (es) 2002-10-01
UA75626C2 (en) 2006-05-15
KR100869721B1 (ko) 2008-11-21
BG66162B1 (bg) 2011-09-30
ATE334128T1 (de) 2006-08-15
EE05404B1 (et) 2011-04-15
US20070129398A1 (en) 2007-06-07
US7893087B2 (en) 2011-02-22
DE60121813T2 (de) 2007-09-20
BG107950A (bg) 2004-03-31
US20100234332A1 (en) 2010-09-16
SI1353919T1 (sl) 2006-12-31
SK7992003A3 (en) 2004-08-03
ES2266291T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
ECSP034672A (es) Derivados de quinuclidina novedosos y composiciones medicinales que los contienen
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
ES462061A1 (es) Un procedimiento para la preparacion de nuevos derivados de tetrahidroisoquinoleina.
ES370394A1 (es) Procedimiento para la preparacion de nuevas 5-11-dihidro-6h-pirido (2,3-b) (1,4) benzodiazepin-6-ona y sus sales.
CO4940477A1 (es) Inhibidores de proteasa
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
AR059076A1 (es) Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas
AR008291A1 (es) Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento.
AR062405A1 (es) Derivados de isoindol
AR044662A1 (es) Compuestos de azetidina
MX9307946A (es) Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.
MX9206169A (es) Derivados de quinoleina, su preparacion y su aplicacion en terapeutica.
HRP20080338T3 (hr) Novi kvaternizirani kinuklidinski esteri
AR041079A1 (es) Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma)
KR910007928A (ko) 신규 벤조[1,8] 나프티리딘 유도체, 그의 제조 및 그를 함유하는 조성물
GB1507717A (en) Benz(de)isoquinoline derivatives
ES2012648A6 (es) Procedimiento para la preparacion de nuevos derivados de 1,4-benzoxazina y 1,4-benzotiazina.
GB1062714A (en) -ß-(4'-acyloxy-4'-piperidyl)-ketones
ES8400440A1 (es) "procedimiento para preparar nuevas triazoloquinazolonas".